AJP - Heart Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 292: H2607-H2612, 2007. First published January 19, 2007; doi:10.1152/ajpheart.01107.2006
0363-6135/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/6/H2607    most recent
01107.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xing, D.
Right arrow Articles by Oparil, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xing, D.
Right arrow Articles by Oparil, S.

Estrogen modulates TNF-{alpha}-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation

Dongqi Xing,* Wenguang Feng,* Andrew P. Miller,1 Nathaniel M. Weathington,2 Yiu-Fai Chen,1 Lea Novak,3 J. Edwin Blalock,2 and Suzanne Oparil1,2

1Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, 2Department of Physiology and Biophysics, and 3Department of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, Alabama

Submitted 10 October 2006 ; accepted in final form 19 January 2007


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
We have previously shown that 17beta-estradiol (E2) attenuates responses to endoluminal injury of the rat carotid artery, at least in part, by decreasing inflammatory mediator expression and neutrophil infiltration into the injured vessel, with a major effect on the neutrophil-specific chemokine cytokine-induced neutrophil chemoattractant (CINC)-2beta. Current studies tested the hypothesis that activated rat aortic smooth muscle cells (RASMCs) express these same inflammatory mediators and induce neutrophil migration in vitro and that E2 inhibits these processes by an estrogen receptor (ER)-dependent mechanism. Quiescent RASMCs treated with E2, the ER{alpha}-selective agonist propyl pyrazole triol (PPT), the ERbeta-selective agonist diarylpropiolnitrile (DPN), or vehicle for 24 h were stimulated with tumor necrosis factor (TNF)-{alpha} and processed for real-time RT-PCR, ELISA, or chemotaxis assays 6 h later. TNF-{alpha} stimulated and E2 attenuated mRNA expression of inflammatory mediators, including P-selectin, intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, monocyte chemoattractant protein (MCP)-1, and CINC-2beta. DPN dose dependently attenuated TNF-{alpha}-induced mRNA expression of CINC-2beta, whereas PPT had no effect. The anti-inflammatory effects of DPN and E2 were blocked by the nonselective ER-inhibitor ICI-182,780. ELISA confirmed the TNF-{alpha}-induced increase and E2-induced inhibition of CINC-2beta protein secretion. TNF-{alpha} treatment of RASMCs produced a twofold increase in neutrophil chemotactic activity of conditioned media; E2 and DPN treatment markedly inhibited this effect. E2 inhibits activated RASMC proinflammatory mediator expression and neutrophil chemotactic activity through an ERbeta-dependent mechanism.

inflammation; vascular smooth muscle cell; arteries

INFLAMMATION plays an important role in the pathogenesis of many forms of vascular disease, including atherosclerosis and the response to acute vascular injury (14, 37). Balloon injury of arteries has been shown to elicit accumulation of inflammatory cells, specifically granulocytes (neutrophils) and monocyte/macrophages, in the adventitia surrounding the injury site within hours after the insult (17, 28, 40). The appearance of inflammatory cells is predated by expression of inflammatory mediators, including adhesion molecules and chemokines, in acutely injured arteries (25) as well as in atherosclerotic and restenotic vessels (18, 22, 28), and is associated with activation of a variety of cell types, including adipocytes and fibroblasts, in adventitial tissues (20, 28). Since vascular smooth muscle cells (VSMCs) have been shown to produce adhesion molecules (3) and chemokines (34) when stimulated with cytokines and because our earlier studies (21) demonstrated that activation and migration of adventitial fibroblasts can be stimulated by media conditioned by VSMCs, we hypothesized that VSMCs are activated early following endoluminal injury, releasing inflammatory mediators that reach the periadventitial space to recruit leukocytes and are the chief effector cells for initiation of the early inflammatory response.

Previous studies in our laboratory have characterized an early estrogen receptor (ER)-dependent anti-inflammatory effect for 17beta-estradiol (E2) in this model of vascular injury (2, 25, 40). We have shown that systemic E2 administration attenuates both expression of inflammatory mediators and infiltration of leukocytes into balloon-injured carotid arteries of ovariectomized (OVX) rats at a very early time point postinjury (25, 40). In this model, we demonstrated a particularly robust effect for E2 in modulating neutrophil chemotaxis via attenuating expression of cytokine-induced neutrophil chemoattractant (CINC)-2beta, a member of the cysteine-x-cysteine (CXC) chemokine family and a potent chemoattractant for neutrophils in vitro and in vivo (23, 24). Based on our hypothesis that VSMCs are the target cells that initiate the injury response, the present in vitro study was designed to define cellular and molecular mechanisms mediating estrogenic anti-inflammatory effects. We tested the estrogen receptor subtype (ER{alpha} or ERbeta) dependence of the anti-inflammatory effect of E2 by employing two recently developed selective ER{alpha} and ERbeta agonists. Based on published observations that 1) tumor necrosis factor (TNF)-{alpha} acts as the body's "fire alarm" (11) and induces the rapid recruitment of leukocytes from the circulation in response to many forms of stress, 2) it is elaborated from diseased bypass grafts and atherosclerotic arteries (8), and 3) our own finding that TNF-{alpha} expression is dramatically upregulated in balloon-injured rat carotid arteries and not affected by E2 administration (25), we used TNF-{alpha} as the inflammatory stimulus in the current study. Since our previous in vivo studies demonstrated robust estrogenic attenuation of injury-induced CINC-2beta expression and of neutrophil infiltration into injured arteries (25, 40), we focused on neutrophil activation and chemotaxis in the current in vitro study.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cell culture. Primary cultures of rat aortic smooth muscle cells (RASMCs) were derived from 10-wk-old female Sprague-Dawley rats (Charles River), as previously described (31). Cells were cultured in complete medium containing phenol red-free DMEM (GIBCO) supplemented with 10% (vol/vol) FBS, 4 mmol/l L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were identified as smooth muscle cells (SMCs) by their characteristic morphology and positive immunostaining for {alpha}-smooth muscle actin ({alpha}-SMA, clone 1A4, DAKO). All experiments were performed using early passage (<5) near-confluent ({approx}95%) cultures that were serum starved for 24 h before treatment.

Initial studies tested whether TNF-{alpha} could stimulate expression of relevant inflammatory chemokines and cytokines in RASMCs and whether pretreatment with E2 could inhibit these inflammatory responses. In these studies, cells were pretreated with E2 (10–7 M) or vehicle (ethanol at a final concentration <0.01%) for 24 h and then incubated with TNF-{alpha} (0.1–2.5 ng/ml) for an additional 6 h.

Subsequent studies assessed the ER subtype dependence of the E2 effect. Cells were pretreated with the selective ERbeta agonist diarylpropiolnitrile (DPN) (10–10-10–7 M) (Tocris Cookson, Ellisville, MO) or the selective ER{alpha} agonist propyl pyrazole triol (PPT) (10–10-10–6 M) (OBITER Research, Urbana, IL) for 24 h, and then incubated with 1 ng/ml TNF-{alpha} for an additional 6 h. Expression of the neutrophil-specific chemokine CINC-2beta was assessed in these studies. To confirm ER dependence of the DPN and E2 effects, subgroups of cells from the above experiments were exposed to the nonselective ER antagonist ICI-182,780 (10–6 M) for 2 h before the E2 (10–7 M) or DPN (10–7 M) pretreatment. For CINC-2beta ELISA and chemotaxis assays, cells were pretreated with E2 (10–7 M) or vehicle for 24 h, followed by TNF-{alpha} (1 ng/ml) treatment for an additional 6 h. Conditioned media were collected to assess CINC-2beta protein concentration and ability to stimulate neutrophil migration.

Real-time quantitative RT-PCR analysis of inflammatory mediators. As described previously (25), total RNA was extracted from cells using TRIzol (Invitrogen, Carlsbad, CA), treated with DNAase I to remove genomic DNA, and then purified by using an RNA purification kit (Invitrogen). The protein- and DNA-free RNA was reverse transcribed to cDNA using the SYBR Green RT-PCR kit (Applied Biosystems, Foster City, CA) and specific primers (described in Ref. 25). cDNA was amplified by PCR in the iCycler for 40 cycles, and relative RNA levels were calculated using the iCycler software and a standard equation (Applied Biosystems). Unknowns were normalized using 18S rRNA and then standardized to the mRNA level of vehicle-treated RASMCs, except for CINC-2beta, monocyte chemoattractant protein (MCP-1) and P-selectin, which were standardized to the mRNA level of TNF-{alpha}-treated RASMCs because their mRNA was undetectable in the vehicle group.

Measurement of CINC-2beta protein concentration. The CINC-2beta concentration in conditioned media of vehicle control and TNF-{alpha} ± E2-treated cells was assayed with the rat GRO/CINC-2beta ELISA kit (IBL, Japan). Briefly, conditioned media (4 ml) were collected and concentrated 10-fold using Centricon concentrators (Millipore, Billerica, MA). Samples were processed according to the manufacturer's instructions. Samples were measured in duplicate, and the CINC-2beta concentration was calculated from the standard curve.

Chemotaxis assays. Human myeloid leukemia HL-60 cells (ATCC, Manassas, VA) were maintained in Iscove's modified medium (ATCC) supplemented with 10% fetal calf serum, 50 µg/ml streptomycin, 2 U/ml penicillin, and 2 mM L-glutamine. For differentiation, cells (3 x 105/ml) were incubated in the presence of 1.3% (vol/vol) DMSO for 4~6 days (Newburger PE) before assessment of their chemotactic responsiveness.

Neutrophil chemotactic activity was assayed in a 96-well modified Boyden chamber (Millipore, Billerica, MA) using differentiated HL-60 (dHL-60) cells. The bottom wells of the chamber were filled with 150 µl of conditioned medium of vehicle control or TNF-{alpha} ± E2-, TNF-{alpha} ± DPN-, or TNF-{alpha} ± PPT-treated cells. To test the CINC-2 dependence of neutrophil chemoattractant activity of conditioned media from TNF-{alpha}-treated cells, anti-CINC-2{alpha}/beta antibody (R&D System, Minneapolis, MN) at a final concentration of 5 µg/ml or PBS (control) was incubated with conditioned media for 30 min at room temperature; 150 µl of the conditioned media-antibody solution were added to the bottom wells of the chamber as described. A polyvinylpyrrolidone-free polycarbonate filter plate with 3-µm pores was placed over the samples, and 100 µl of the dHL-60 cell suspension (2 x 106 cells/ml) were placed into the upper wells. The chambers were incubated in humidified air with 5% CO2 at 37°C for 90 min. The upper portion was then removed, and four photomicrographs (200x) per well were digitally recorded using an Olympus IX70 microscope and Perkin-Elmer Ultraview image capture equipment. Cell counts were made from these images. For ease of comparison of results between experiments, data were standardized to a chemotactic index with cell migration to conditioned media of vehicle-treated RASMCs as a baseline (25).

Statistical analysis. Data are expressed as means ± SE. Statistical analysis was performed with one-way ANOVA or Student's t-test, as appropriate. Values of P < 0.05 were considered significant.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Real-time quantitative RT-PCR analysis showed that TNF-{alpha} (0.1–2.5 ng/ml) dose dependently stimulated expression of chemokines (CINC-2beta and MCP-1) and adhesion molecules [intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and P-selectin] (results for CINC-2beta shown in Fig. 1). A TNF-{alpha} concentration of 1 ng/ml was chosen for further experiments because it was the minimum effective dose for all mediators. All mediators were expressed at low or undetectable levels in unstimulated vehicle-treated RASMCs (Fig. 2). Pretreatment with E2 (10–7 M) significantly inhibited expression of CINC-2beta, MCP-1, ICAM-1, VCAM-1, and P-selectin in cells treated with TNF-{alpha} (1 ng/ml, Fig. 2). Inhibition of these chemokines and adhesion molecules expression was abolished by the nonselective ER antagonist ICI-182,780 (10–6 M), indicating ER dependence (Fig. 2).


Figure 1
View larger version (7K):
[in this window]
[in a new window]

  		Fig. 1. Tumor necrosis factor (TNF)-{alpha} dose dependently increases mRNA expression of cytokine-induced neutrophil chemoattractant (CINC)-2beta in rat aortic smooth muscle cells (RASMCs). Cells were grown to subconfluence ({approx}95%) in six-well plates, deprived of serum for 24 h, and then treated with TNF-{alpha} (0.5–2.5 ng/ml) for an additional 6 h. Data, expressed as means ± SE, are from real-time quantitative RT-PCR assays and are normalized by 18S RNA and then standardized to the mean mRNA level of the RASMCs treated with TNF-{alpha} at the 0.5 ng/ml dose. UD, undetectable; *P < 0.05 vs. vehicle-treated RASMCs.

 

Figure 2
View larger version (15K):
[in this window]
[in a new window]

  		Fig. 2. 17beta-Estradiol (E2, 10–7 M) inhibits TNF-{alpha}-induced mRNA expression of chemokines (left) and adhesion molecules (right) in RASMCs, and this effect is abolished by ICI-182,780. Cells were grown to subconfluence ({approx}95%) in six-well plates, deprived of serum for 24 h, pretreated with 10–7 M E2 or vehicle for 24 h, and then treated with TNF-{alpha} (1 ng/ml) for an additional 6 h. ICI-182,780 (10–6 M) was given to cells at 2 h before E2 treatment in some experiments. Data, expressed as means ± SE, are from real-time quantitative RT-PCR assays and are normalized by 18S RNA. Data for P-selectin, CINC-2beta, and monocyte chemoattractant protein (MCP)-1 are standardized to the mean mRNA level of the TNF-{alpha}-treated RASMCs. Data for intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 are standardized to the mean mRNA level of the vehicle-treated RASMCs. *P < 0.05 vs. respective vehicle-treated RASMCs; #P < 0.05 vs. respective TNF-{alpha}-treated RASMCs.

 
The selective ER-beta agonist DPN dose dependently inhibited TNF-{alpha} (1 ng/ml)-induced expression of CINC-2beta over the concentration range 10–10 to 10–7 M (Fig. 3). This effect was blocked by treatment with ICI-182,780 (10–6 M), confirming its ER dependence (Fig. 3). The selective ER-{alpha} agonist PPT, over the dose range of 10–10-10–6 M, had no effect on CINC-2beta expression in TNF-{alpha} (1 ng/ml)-treated cells (Fig. 4), suggesting that the anti-inflammatory effects of E2 in RASMCs are selectively mediated by ERbeta and not ER{alpha}.


Figure 3
View larger version (10K):
[in this window]
[in a new window]

  		Fig. 3. The ERbeta-selective agonist diarylpropiolnitrile (DPN) inhibits TNF-{alpha}-induced CINC-2beta mRNA expression in RASMCs, and this effect is abolished by ICI-182,780. Cells were grown to subconfluence ({approx}95%) in six-well plates, deprived of serum for 24 h, pretreated with DPN (10–10-10–7 M) or vehicle for 24 h, and then treated with TNF-{alpha} (1 ng/ml) for an additional 6 h. ICI-182,780 (10–6 M) was given to cells at 2 h before DPN treatment in some experiments. Data are from real-time RT-PCR assays and normalized by 18S RNA and then standardized to the mean mRNA level of the TNF-{alpha}-treated RASMCs. Results are means ± SE. *P < 0.05 vs. vehicle-treated RASMCs; #P < 0.05 vs. TNF-{alpha}-treated RASMCs.

 

Figure 4
View larger version (9K):
[in this window]
[in a new window]

  		Fig. 4. ER{alpha}-selective agonist propyl pyrazole triol (PPT) has no effect on TNF-{alpha}-induced CINC-2beta mRNA expression in RASMCs. Cells were grown to subconfluence ({approx}95%) in six-well plates, deprived of serum for 24 h, pretreated with PPT (10–10-10–6 M) or vehicle for 24 h, and then treated with TNF-{alpha} (1 ng/ml) for an additional 6 h. Data are from real-time RT-PCR assays and normalized by 18S RNA and then standardized to the mean mRNA level of the TNF-{alpha}-treated RASMCs. Results are means ± SE. *P < 0.05 vs. vehicle-treated RASMCs.

 
CINC-2beta protein concentration was quantified in conditioned media from RASMCs using a double sandwich ELISA technique (Fig. 5). E2 had no significant effect on CINC-2beta protein concentration in conditioned media from vehicle-treated RASMCs. TNF-{alpha} increased CINC-2beta protein levels 2.7-fold compared with vehicle-treated control cells, and E2 pretreatment completely abolished the TNF-{alpha}-induced increase in CINC-2beta expression.


Figure 5
View larger version (5K):
[in this window]
[in a new window]

  		Fig. 5. E2 inhibits TNF-{alpha}-induced CINC-2beta protein expression in RASMCs. Cells were grown to subconfluence ({approx}95%) in six-well plates, deprived of serum for 24 h, pretreated with 10–7 M E2 or vehicle for 24 h, and then treated with TNF-{alpha} (1 ng/ml) for an additional 6 h, and conditioned media were collected. Data, expressed as means ± SE, are from a double sandwich ELISA assay. *P < 0.05 vs. vehicle-treated RASMCs; #P < 0.05 vs. TNF-{alpha}-treated RASMCs.

 
To assess the functional significance of the TNF-{alpha} and E2- or DPN-induced alterations in CINC-2beta expression, the ability of conditioned media from cells subjected to these treatments to stimulate migration of dHL-60 cells was assayed. Chemotactic activity was normalized to conditioned media from vehicle-treated RASMCs as described in MATERIALS AND METHODS. There was no significant difference in the chemotactic activity of conditioned media derived from vehicle-treated versus E2-, DPN-, and PPT-treated cells. TNF-{alpha} treatment induced a marked (2.2-fold) increase in dHL-60 cell migration, and E2 pretreatment of RASMCs significantly attenuated the TNF-{alpha}-induced effect on dHL-60 cell migration (by 48%, P < 0.01) (Fig. 6). DPN, but not PPT, mimicked the inhibitory effect of E2 on TNF-{alpha} treatment-induced dHL-60 cell migration (by 69%, P < 0.01). To test the CINC-2 dependence of neutrophil chemoattractant activity of conditioned media from TNF-{alpha}-treated cells, conditioned media from separate groups of cells were preincubated with selective anti-CINC-2 antibody. Antibody treatment neutralized chemotactic activity of conditioned media by 63%, verifying its CINC-2 dependence.


Figure 6
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 6. Neutrophil chemotactic activity of conditioned media from TNF-{alpha}-stimulated RASMCs is blocked by E2 and DPN. Cells were grown to subconfluence ({approx}95%) in 75-mm2 flasks, deprived of serum for 24 h, and pretreated with 10–7 M E2, 10–7 M DPN, 10–7 M PPT, or vehicle, respectively, for 24 h followed by TNF-{alpha} (1 ng/ml) treatment for an additional 6 h. Conditioned media were collected. Selective anti-CINC-2 antibody (5 µg/ml) partially neutralized neutrophil chemotactic activity of conditioned media from TNF-{alpha}-treated cells. Results are means ± SE normalized by vehicle-treated RASMCs. *P < 0.05 vs. vehicle-treated RASMCs; #P < 0.05 vs. TNF-{alpha}-treated RASMCs.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
This in vitro study demonstrates that isolated RASMCs express high levels of proinflammatory mediators, including the neutrophil- and monocyte-selective chemokines CINC-2beta and MCP-1, when activated by TNF-{alpha} and that estrogen inhibits this process via and ERbeta-dependent mechanism. Media conditioned by activated SMCs directed the migration of neutrophils, and this effect was partially inhibited by pretreatment with anti-CINC-2 antibody, indicating that the CINC-2beta secreted into the conditioned media was functional. Treatment with an ERbeta-selective agonist dose dependently inhibited CINC-2beta expression and reduced the chemotactic activity of media conditioned by TNF-{alpha}-treated SMCs. Together, these data support the concept that arterial SMCs are important sources of proinflammatory mediators in the setting of acute vascular injury, triggering a robust inflammatory response that is amplified by recruitment of neutrophils and monocytes into the adventitial domain of the injured vessel and by activation and migration of adventitial fibroblasts into the neointima (25, 40).

The CXC chemokines are powerful mediators of neutrophil recruitment. A representative member of the CXC chemokine family is IL-8, which is a major chemoattractant for neutrophils in humans (29, 39). In rats, no homologue of IL-8 has been identified, and the CXC chemokines that recruit neutrophils are termed CINC (1, 26). Four CXC chemokines, including CINC (or CINC-1), CINC-2{alpha}, CINC-2beta, and MIP-2 (or CINC-3), have been identified in rats (10, 27, 32). CINC-2 has two splicing isoforms, CINC-2{alpha} and CINC-2beta (33), which differ in the three amino acids at the COOH terminus (27). Both CINC-2{alpha} and CINC-2beta are chemotactic for neutrophils, with an effect at a 10 nM concentration (80 ng/ml) (27). CINCs are structurally related to one another and share many functions. They have an ability to attract neotrophils and have effects on other neotrophil functions, including adhesion molecule expression, intracellular calcium influx, and phagocytosis (27, 32). Upregulation of CINC-2 has been correlated with neutrophil infiltration in many disease models, including acute right ventricular failure following pulmonary embolism (35) and ischemia-reperfusion injury of the liver (41). The present study reveals marked estrogenic modulation of CINC mRNA and protein expression in TNF-{alpha}-stimulated RASMCs, consistent with our previous in vivo reports of attenuated CINC-2beta expression and neutrophil infiltration in injured arteries with E2 treatment. To our knowledge, this report is the first in vitro study of CINC or CXCR2 ligand regulation by E2 in RASMCs.

The finding that antibodies to CINC-2 did not completely ablate the chemotactic avtivity of supernates from TNF-{alpha}-treated RASMCs was not unexpected because there are undoubtedly other neutrophil chemoattractants in such supernates. These might induce leukotriene B4 (9) and the recently described tripeptide, PGP (38). It is, however, particularly interesting that about two-thirds of the chemotactic activity of supernates from TNF-{alpha}-stimulated RASMCs is apparently due to CINC-2 and that a similar amount of chemotactic activity is inhibited by E2 (48%) or DPN (69%). This suggests that the effects of estrogen on neutrophil chemotaxis are likely due to the ability of estrogen to inhibit CINC-2 production.

In the current study, we employed the selective ERbeta agonist DPN and the selective ER{alpha} agonist PPT to define the relevant ER subtypes involved in the anti-inflammatory effects of E2 on RASMCs. Because of its selective binding affinity, DPN is 30- to 70-fold more potent as an agonist of ERbeta than ER{alpha} (4). Supporting its anti-inflammatory effects, DPN has been shown to suppress IL-6 promoter activity in human endothelial cancer (HEC-1) cells in vitro to the same extent as E2 (15). In a male rat model of trauma-hemorrhage, DPN, and not PPT, protected against lung injury, with associated reductions of inducible nitric oxide synthase and IL-6 expression (42), and restored cardiac function, with associated upregulation of heat shock proteins (43). A further study in this model demonstrated that DPN, in subcutaneous doses of 5 µg/kg administered during resuscitation, inhibited myeloperoxidase activity and ELISA-measured levels of CINC-1, CINC-3, and ICAM-1 in the lung, suggesting an important role in regulation of neutrophil infiltration after acute injury (44).

A related compound ERB-041 has 200-fold increased binding activity for ERbeta over ER{alpha} and is orally active (16). ERB-041 in oral doses as low as 1 mg·kg–1·day–1 has been shown to reverse chronic diarrhea and ameliorate colonic lesions in a transgenic rat model of inflammatory bowel disease (HLA-B27) and shown to reduce joint inflammation in the Lewis rat adjuvant-arthritis model (16). In the latter model, mRNA expression profiling in the spleen, lymph nodes, and liver, and global analysis of the plasma proteome revealed disease-related alterations in a large number of genes and proteins related to immune responses that were completely or partially reversed by ERB-041 administration (12). When taken together, these findings support the current study and suggest the possibility that ERbeta mediates the anti-inflammatory effects of estrogen in some tissues.

PPT is ~400 times more potent as an agonist for ER{alpha} than for ERbeta (4). PPT in doses of 0.3–15 mg·kg–1·day–1 administered subcutaneously has been shown to evoke a number of physiologically relevant E2-induced tissue responses (uterine weight gain, prevention of OVX-induced body weight gain and loss of bone mineral density, reduction in plasma cholesterol levels, increases in brain progesterone receptor mRNA levels, and prevention of experimentally induced hot flushes) in rats (24). In the vasculature, PPT, and not DPN, has been shown to mediate estrogenic vasodilatory responses at physiological doses: Acute administration of PPT (10–13-10–7 M) to precontracted aortic rings from intact female rats dose dependently induced an ER-dependent vasodilatory response equal to that of E2, whereas DPN had no acute effect on vasomotion (4).

Studies with knockout mice support important ER{alpha}-mediated protective effects on vascular injury (19, 30). Pare et al. (30) showed that complete ER{alpha} knockout mice (ERKOST) lost the protective effects of E2 in a wire injury model. In this study, the primary outcomes of change in medial area, proteoglycan deposition, and VSMC proliferation (by bromodeoxyuridine staining) were not altered by E2 administration in the ERKOST animals. In contrast, E2 did protect against wire injury-induced increases in vascular medial area and proliferation of VSMCs in ERbeta knockout mice (18). ER{alpha}, but not ERbeta, has also been shown to mediate the reendothelialization effect of E2 after electric carotid injury in mice with targeted disruptions of ER genes (6). As we have previously demonstrated, E2 restores endothelial cell function after denudation in the balloon injury model of the rat carotid artery as well (38), but this is a late event that occurs 2–4 wk postinjury (6).

In vitro studies support ER subtype and cell type-specific modulatory effects of E2 on vascular cell function (13). Selective ERbeta and ER{alpha} mRNA anti-sense oligomers were used to examine the ER subtype dependence of E2-induced inhibition of PDGF-BB-induced p38 and p42/44 mitogen-activated protein kinase phosphorylation, migration, and proliferation in porcine SMCs, and endothelial cells. The inhibitory effects of E2 on porcine SMCs were abrogated by downregulation of ERbeta protein expression, whereas downregulation of ER{alpha} had no effect. In contrast, downregulation of ER{alpha} expression in porcine aortic endothelial cells inhibited E2-induced p38 and p42/44 mitogen-activated protein kinase activation, whereas downregulation of ERbeta had no effect. These observations are relevant to our in vivo model of balloon injury of the rat carotid artery, because the injured area is denuded of endothelium for several weeks and the early injury response is driven by activated SMCs and infiltrating leukocytes. Thus modulatory effects of ERbeta activation on SMC-initiated inflammatory responses likely play an important role in inhibiting early inflammatory changes in the setting of endoluminal vascular injury.

Limitations of the current study include use of ER agonists to delineate ER subtype-specific effects in stimulated VSMCs. These agents, while the best available, are not pure ERbeta or ER{alpha} subtype agonists. While we recognize that perturbation of ERbeta and ER{alpha} signaling with pharmacological ER antagonists and/or siRNA strategies might theoretically provide superior approaches, no good selective ERbeta and ER{alpha} antagonists are available, and small interfering RNA technology has not been successful in modulating E2 signaling in SMCs in our hands. We have not tested whether ERbeta activation, as studied here, is sufficient to attenuate neointima formation in animals subjected to endoluminal injury in vivo. We are aware that other ER{alpha}-modulated processes, e.g., reendothelialization, contribute to the injury response at later time points. Further study is needed to elucidate the ER subtype-specific effects of E2 in modulating injury responses in arteries.

Taken together, our in vivo and in vitro results suggest that medial VSMCs are an important source for the proinflammatory mediators that trigger the response to acute endoluminal arterial injury. VSMCs of injured arteries are initial targets for the anti-inflammatory actions of E2. In VSMCs, ERbeta appears to be the dominated ER subtype that contributes to the anti-inflammatory effects of E2.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported, in part, by National Heart, Lung, and Blood Institute Grants HL-07457, HL-64614, HL-75211, HL-68806; by American Heart Association Grant AHA-0425455B; and by a Vascular Biology Working Group Fellows Award.


   FOOTNOTES
 

Address for reprint requests and other correspondence: D. Xing, 1014 Zeigler Research Bldg., Univ. of Alabama at Birmingham, UAB Station, Birmingham, AL 35294 (E-mail: dqxing{at}uab.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

* D. Xing and W. Feng contributed equally to this study. Back


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A, Maysushima K, Murphy P, Nomiyama H, Oppenheim J, Rot A, Schall T, Tsang M, Thorpe R, Van Damme J, Wadhwa M, Yoshie O, Zlotnik A, Zoon K, the IUIS/WHO Subcommittee on Chemokine Nomenclature. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 22: 1067–1068, 2002.[CrossRef][Web of Science][Medline]
  2. Bakir S, Mori T, Durand J, Chen YF, Thompson JA, Oparil S. Estrogen-induced vasoprotection is estrogen receptor dependent: evidence from the balloon-injured rat carotid artery model. Circulation 101: 2342–2344, 2000.[Abstract/Free Full Text]
  3. Bishop-Bailey D, Burke-Gaffney A, Hellewell PG, Pepper JR, Mitchell JA. Cyclo-oxygenase-2 regulates inducible ICAM-1 and VCAM-1 expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 249: 44–47, 1998.[CrossRef][Web of Science][Medline]
  4. Bolego C, Cignarella A, Sanvito P, Pelosi V, Pellegatta F, Puglisi L, Pinna C. The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-{alpha} agonists and is abolished by estrogen deprivation. J Pharmacol Exp Ther 313: 1203–1208, 2005.[Abstract/Free Full Text]
  5. Bolego C, Vegeto E, Pinna C, Maggi A, Cignarella A. Selective agonists of estrogen receptor isoforms: new perspectives for cardiovascular disease. Arterioscler Thromb Vasc Biol 26: 2192–2199, 2006.[Abstract/Free Full Text]
  6. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, Arnal JF. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 103: 423–428, 2001.[Abstract/Free Full Text]
  7. Chen YF, Oparil S. Effects of sex steroids in vascular injury. In: Endocrinology of Cardiovascular Function, edited by Levin ER and Nadler JL. New York: Kluwer Academic, 1998, p. 45–59.
  8. Christiansen JF, Hartwig D, Bechtel JF, Kluter H, Sievers H, Schonbeck U, Bartels C. Diseased vein grafts express elevated inflammatory cytokine levels compared with atherosclerotic coronary arteries. Ann Thorac Surg 77: 1575–1579, 2004.[Abstract/Free Full Text]
  9. Dahinden CA, Clancy RM, Hugli TE. Stereospecificity of leukotriene B4 and structure-function relationships for chemotaxis of human neutrophils. J Immunol 133: 1477–1482, 1984.[Abstract]
  10. Driscoll KE, Hassenbein DG, Howard BW, Isfort RJ, Cody D, Tindal MH, Succhanek M, Carter JM. Cloning, expression, and functional characterization of rat MIP-2: a neutrophil chemoattractant and epithelial cell mitogen. J Leukoc Biol 58: 359–364, 1995.[Abstract]
  11. Feldmann M, Pusey CD. Is there a role for TNF-{alpha} in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol 17: 1243–1252, 2006.[Abstract/Free Full Text]
  12. Follettie MT, Pinard M, Keith JC, Wang L, Chelsky D, Hayward C, Kearney P, Thibault P, Paramithiotis E, Dorner AJ, Harris HA. Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with the estrogen receptor-beta selective agonist ERB-041. Endocrinology 147: 714–723, 2006.[Abstract/Free Full Text]
  13. Geraldes P, Sirois MG, Tanguay JF. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ Res: 399–405, 2003.
  14. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685–1695, 2005.[Free Full Text]
  15. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 206: 13–22, 2003.[CrossRef][Web of Science][Medline]
  16. Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC Jr. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 144: 4241–4249, 2003.[Abstract/Free Full Text]
  17. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 90: 488–494, 2002.[Abstract/Free Full Text]
  18. Inoue S, Egashira K, Ni W, Kitamoto S, Usui M, Otani K, Ishibashi M, Hiasa K, Nishida K, Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 106: 2700–2706, 2002.[Abstract/Free Full Text]
  19. Karas RH, Hodgin JB, Kwoun M, Krege JH, Aronovitz M, Mackey W, Gustafsson JA, Korach KS, Smithies O, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient mice. Proc Natl Acad Sci USA 96: 15133–15136, 1999.[Abstract/Free Full Text]
  20. Li G, Chen SJ, Oparil S, Chen YF, Thompson JA. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation 101: 1362–1365, 2000.[Abstract/Free Full Text]
  21. Li G, Chen YF, Greene GL, Oparil S, Thompson JA. Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 100: 1639–1645, 1999.[Abstract/Free Full Text]
  22. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 108: 2498–2504, 2003.[Abstract/Free Full Text]
  23. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Eng J Med 338: 436–445, 1998.[Free Full Text]
  24. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44: 4230–4251, 2001.[CrossRef][Web of Science][Medline]
  25. Miller AP, Feng W, Xing D, Weathington NM, Blalock JE, Chen YF, Oparil S. Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 110: 1664–1669, 2004.[Abstract/Free Full Text]
  26. Modi WS, Yoshimura T. Isolation of novel GRO genes and a phylogenetic analysis of the CXC chemokine subfamily in mammals. Mol Biol Evol 16: 180–193, 1999.[Abstract]
  27. Nakagawa H, Komorita N, Shibata F, Ikesue A, Konishi K, Fujioka M, Kato H. Identification of cytokine-induced neutrophil chemoattractants (CINC), rat GRO/CINC-2 {alpha} and CINC-2beta, produced by granulation tissue in culture: purification, complete amino acid sequences and characterization. Biochem J 301: 545–550, 1994.[Web of Science][Medline]
  28. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, Wilcox JN. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 104: 2228–2235, 2001.[Abstract/Free Full Text]
  29. Oppenheim J, Zachariae C, Mukaida N, Matushima K. Properties of the novel pro-inflammatory supergene "interkrine" cytokine family. Annu Rev Immunol 9: 617–648, 1991.[Web of Science][Medline]
  30. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90: 1087–1092, 2002.[Abstract/Free Full Text]
  31. Ross R. Growth of smooth muscle cell in culture and formation of elastic fibers. J Cell Biol 50: 172–186, 1971.[Abstract/Free Full Text]
  32. Shibata F, Konishi K, Kato H, Komorita N, Al-Mokdad M, Fujioka M, Nakagawa H. Recombinant production and biological properties of rat cytokines-induced neutrophil chemoattractants, GRO/CINC-2 {alpha}, CINC-2 and CINC-3. Eur J Biochem 231: 306–311, 1995.[Web of Science][Medline]
  33. Shibata F, Konishi K, Nakagawa H. Gene structure, cDNA cloning, and expression of the rat cytokine-induced neutrophil chemoattractant-2 (CINC-2) gene. Cytokine 10: 169–174, 1998.[CrossRef][Web of Science][Medline]
  34. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P, Ceska M, Lindley I, Colotta F, Mantovani A. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb 11: 1166–1174, 1991.[Abstract/Free Full Text]
  35. Watts JA, Zagorski J, Gellar MA, Stevinson BG, Kline JA. Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J Mol Cell Cardiol 41: 296–307, 2006.[CrossRef][Web of Science][Medline]
  36. Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL, Kraneveld AD, Galin FS, Folkerts G, Nijkamp FP, Blalock JE. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 12: 317–323, 2006.[CrossRef][Web of Science][Medline]
  37. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22: 1769–1776, 2002.[Abstract/Free Full Text]
  38. White CR, Shelton J, Chen SJ, Darley-Usmar V, Allen L, Nabors C, Sanders PW, Chen YF, Oparil S. Estrogen restores endothelial cell function in an experimental model of vascular injury. Circulation: 1624–1630, 1997.
  39. Wirthlin MR, Hussain MZ. Clinical and light microscopic observations of gingivitis and early ligature-induced periodontitis in the cynomolgus monkey. J Periodontol 63: 533–539, 1992.[Web of Science][Medline]
  40. Xing D, Miller A, Novak L, Rocha R, Chen YF, Oparil S. Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 109: 234–241, 2004.[Abstract/Free Full Text]
  41. Yonezawa K, Yamamoto Y, Yamamoto H, Ishikawa Y, Uchinami H, Taura K, Nakajima A, Yamaoka Y. Suppression of tumor necrosis factor-alpha production and neutrophil infiltration during ischemia-reperfusion injury of the liver after heat shock preconditioning. J Hepatol 35: 619–627, 2001.[CrossRef][Web of Science][Medline]
  42. Yu HP, Hsieh YC, Suzuki T, Choudhry MA, Schwacha Chaudry IH. Salutory effects of estrogen receptor-beta agonist on lung injury after trauma-hemorrhage. Am J Physiol Lung Cell Mol Physiol 290: L1004–L1009, 2006.[Abstract/Free Full Text]
  43. Yu HP, Shimizu T, Choudhry MA, Hsieh YC, Suzuki T, Bland KI, Chaudry IH. Mechanism of cardioprotection following trauma-hemorrhagic shock by a selective estrogen receptor-beta agonist: up-regulation of cardiac heat shock factor-1 and heat shock proteins. J Mol Cell Cardiol 40: 185–194, 2006.[CrossRef][Web of Science][Medline]
  44. Yu HP, Shimizu T, Hsieh YC, Suzuki T, Choudhry MA, Schwacha MG, Chaudry IH. Tissue-specific expression of estrogen receptors and their role in the regulation of neutrophil infiltration in various organs following trauma-hemorrhage. J Leukoc Biol 79: 963–970, 2006.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 LupusHome page
E Rodriguez, J Guevara, A Paez, E Zapata, M. Collados, T. Fortoul, R Lopez-Marure, F Masso, and L. Montano
The altered expression of inflammation-related molecules and secretion of IL-6 and IL-8 by HUVEC from newborns with maternal inactive systemic lupus erythematosus is modified by estrogens
Lupus, December 1, 2008; 17(12): 1086 - 1095.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. Xing, W. Feng, L. G. Not, A. P. Miller, Y. Zhang, Y.-F. Chen, E. Majid-Hassan, J. C. Chatham, and S. Oparil
Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H335 - H342.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
V. M. Miller and S. P. Duckles
Vascular Actions of Estrogens: Functional Implications
Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/6/H2607    most recent
01107.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xing, D.
Right arrow Articles by Oparil, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xing, D.
Right arrow Articles by Oparil, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.